Celltrion coronavirus treatment cleared for clinical trials

Home > Business > Industry

print dictionary print

Celltrion coronavirus treatment cleared for clinical trials

Korea's Ministry of Food and Drug Safety said Thursday that it has approved advanced clinical trials for Celltrion's CT-P59 treatment material that could be used to combat the novel coronavirus.
The Phase 2 and 3 trials to be conducted on the antiviral antibody treatment candidate substance developed by the local biopharmaceutical firm come after initial tests carried out on healthy people showed the material is not harmful for use.
The next stage of trials will be conducted on people with mild and severe symptoms, which will allow researchers to better check CT-P59's efficacy against Covid-19 and its overall safety, the ministry said.
The Phase 2 trials will be conducted on 300 people to determine the appropriate dosage that needs to be given. Phase 3, involving some 720 people, will be carried out to see if the candidate material is actually effective against viral infections, according to the ministry.
Celltrion said that besides Korea, it has requested clinical trials of CT-P59 in the United States, Romania and three other countries as part of its ongoing effort to find viable treatment materials to fight the coronavirus pandemic.
Related to the latest approval, the state-run Korea National Enterprise for Clinical Trials said earlier in the day that Seoul has approved 23 different clinical trials for treatment candidate materials. Of these, 21 are treatment drugs materials and two are potential vaccines.

More in Industry

Chuseok delivery strike canceled as headcount increased

BMW Motorrad channels 1936 for its latest bike

Battery business IPO won't affect LG Chem's controlling stake, company says

Hyundai Construction Equipment signs Algeria forklift deal

FSS permits financial sector workers to use networks remotely

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now